239 related articles for article (PubMed ID: 38575524)
1. Opportunities and challenges for human papillomavirus vaccination in China.
Zhao C; Zhao Y; Li J; Li M; Shi Y; Wei L
Hum Vaccin Immunother; 2024 Dec; 20(1):2329450. PubMed ID: 38575524
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.
Li M; Zhao C; Zhao Y; Li J; Wei L
Front Immunol; 2023; 14():1112750. PubMed ID: 36993948
[TBL] [Abstract][Full Text] [Related]
3. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
Kiendrébéogo JA; Sidibe ARO; Compaoré GB; Nacanabo R; Sory O; Ouédraogo I; Nawaz S; Schuind AE; Clark A
BMC Health Serv Res; 2023 Dec; 23(1):1338. PubMed ID: 38041075
[TBL] [Abstract][Full Text] [Related]
5. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
6. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions.
Li J; Gao JJ; Li N; Wang YW
Arch Virol; 2021 Mar; 166(3):853-862. PubMed ID: 33486629
[TBL] [Abstract][Full Text] [Related]
7. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
9. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
12. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
13. Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
Mwenda V; Jalang'o R; Miano C; Bor JP; Nyangasi M; Mecca L; Were V; Kariithi E; Pecenka C; Schuind A; Abbas K; Clark A
Vaccine; 2023 Jun; 41(29):4228-4238. PubMed ID: 37296015
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
[TBL] [Abstract][Full Text] [Related]
15. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
[TBL] [Abstract][Full Text] [Related]
16. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
19. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of human papillomavirus vaccination in the Philippines.
Llave CL; Uy MEV; Lam HY; Aldaba JG; Yacapin CC; Miranda MB; Valverde HA; Silva WT; Nawaz S; Slavkovsky RC; Mooney J; Vodicka EL
Vaccine; 2022 Jun; 40(27):3802-3811. PubMed ID: 35606237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
